PubMed- https://t.co/ILB4WK9cwE Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. @HUCA_Asturias #publiHUCA #Oncology Full text:
1,586 followers
3,054 followers
4,195 followers
RT @IDIVALdireccion: High-sensitive dPCR accurately identified patients with KRAS, NRAS, BRAF and PIK3CA mutations. Data from Phase II the…
4,195 followers
RT @IDIVALdireccion: High-sensitive dPCR accurately identified patients with KRAS, NRAS, BRAF and PIK3CA mutations. @IDIBELL_cat @CIBERONC…